XORTX Therapeutics Inc (XRTX) - Total Assets
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) holds total assets worth CA$2.81 Million CAD (≈ $2.03 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can XORTX Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.
XORTX Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how XORTX Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See XRTX net asset value for net asset value and shareholders' equity analysis.
XORTX Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
XORTX Therapeutics Inc's total assets of CA$2.81 Million consist of 65.4% current assets and 34.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 60.4% |
| Accounts Receivable | CA$17.64K | 0.4% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$183.11K | 4.5% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how XORTX Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XRTX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XORTX Therapeutics Inc's current assets represent 65.4% of total assets in 2024, a decrease from 77.4% in 2018.
- Cash Position: Cash and equivalents constituted 60.4% of total assets in 2024, up from 20.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 22.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 4.5% of total assets.
XORTX Therapeutics Inc Competitors by Total Assets
Key competitors of XORTX Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
XORTX Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.62 | 1.40 | 1.99 |
| Quick Ratio | 1.62 | 1.40 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$520.07K | CA$693.64K | CA$1.02 Million |
XORTX Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between XORTX Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -25.1% |
| Total Assets | CA$4.09 Million |
| Market Capitalization | $3.55 Million USD |
Valuation Analysis
Near Book Valuation: The market values XORTX Therapeutics Inc's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: XORTX Therapeutics Inc's assets decreased by 25.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for XORTX Therapeutics Inc (2018–2024)
The table below shows the annual total assets of XORTX Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$4.09 Million ≈ $2.96 Million |
-25.12% |
| 2023-12-31 | CA$5.47 Million ≈ $3.96 Million |
-55.70% |
| 2022-12-31 | CA$12.34 Million ≈ $8.93 Million |
-43.98% |
| 2021-12-31 | CA$22.04 Million ≈ $15.94 Million |
+862.07% |
| 2020-12-31 | CA$2.29 Million ≈ $1.66 Million |
+110.52% |
| 2019-12-31 | CA$1.09 Million ≈ $787.03K |
-14.01% |
| 2018-12-31 | CA$1.27 Million ≈ $915.26K |
-- |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more